Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
Report Scope:
This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report.
Report Includes:
31 data tables and 63 additional tables
An overview of the global market for the technologies for prevention and treatment of prostate cancer
Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region
Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas
Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations
Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer
Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer
Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios
Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer
Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies
Profiles of leading market participants
Companies MentionedABBOTT
ACCURAY INC.
ASTELLAS PHARMA INC.
ASTRAZENECA PLC
BAYER AG
DANAHER CORP.
DENDREON PHARMACEUTICALS LLC
ELEKTA
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
PFIZER INC.
SANOFI
SIEMENS HEALTHINEERS AG